Resverlogix (RVX.TO) Osake Kurssi
Resverlogix Kurssi
Resverlogixn liikevaihto on supistunut 26,9 % vuodessa viimeisten 4 vuoden aikana 82 875,89 USD:een. Osakekohtainen tulos on laskenut 74,6 % vuodessa viimeisten 8 vuoden aikana. Resverlogixn nettomarginaali on nyt −26 691,8 %, laskenut −5 707,1 %:sta muutama vuosi sitten.
Resverlogix osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Resverlogix liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Resverlogix -osakkeesta
The business model of Resverlogix Corp is focused on developing innovative therapies in the field of epigenetics to address unmet medical needs. The company specializes in the discovery and development of small molecules that target specific proteins involved in the regulation of gene expression. Resverlogix Corp aims to provide novel treatments for conditions such as cardiovascular diseases and other related disorders. By leveraging their expertise in epigenetics, the company strives to offer groundbreaking therapies that have the potential to significantly improve patients' lives.
Resverlogix Corp is primarily active in the pharmaceutical industry.
Some of the main competitors of Resverlogix Corp in the market include Novartis AG, Pfizer Inc., Amgen Inc., and AstraZeneca PLC.
Resverlogix Corp, founded in 2001, is a Canadian biotechnology company specializing in developing innovative therapies for cardiovascular diseases. The company focuses on addressing unmet medical needs, primarily targeting high-risk patients with chronic diseases. Resverlogix Corp is at the forefront of pioneering epigenetic drug discovery and development, specifically targeting BET bromodomain inhibition. Their leading compound, Apabetalone, has shown promising results in clinical trials, demonstrating its potential to reduce major adverse cardiovascular events. With a commitment to improving patient outcomes and advancing cardiovascular health, Resverlogix Corp has emerged as a prominent player in the biotech industry.
Resverlogix Corp has achieved several significant milestones in its journey. The company successfully completed Phase 3 clinical trials for its lead drug candidate, apabetalone, for the treatment of high-risk cardiovascular diseases. Moreover, Resverlogix Corp received a Special Protocol Assessment from the U.S. FDA for the Phase 3 BETonMACE trial, indicating the agency's support for the trial design. The company's achievements also include securing strategic partnerships and collaborations with renowned pharmaceutical companies, enhancing its research capabilities and market presence. These milestones demonstrate Resverlogix Corp's commitment to advancing innovative treatments for serious diseases and highlights its strong potential for growth and success in the pharmaceutical industry.
Resverlogix Corp is primarily present in Canada and the United States.
Resverlogix Corp represents values of innovation, excellence, and commitment to improving patients' lives. With a strong corporate philosophy focused on advancing groundbreaking medical treatments, Resverlogix Corp strives to redefine the standard of care in cardiovascular diseases. Through their leading-edge drug development platform, BETonMACE™, the company aims to deliver transformative therapies that target unmet medical needs. Resverlogix Corp is dedicated to scientific excellence, collaboration with global experts, and ensuring the highest ethical standards in their research and development endeavors. Through their unwavering dedication, Resverlogix Corp is committed to making a positive impact on the lives of patients worldwide.
5 analyytikkoa arvioi tällä hetkellä Resverlogix-osaketta: 4 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Nykyisellä valuuttakurssilla Resverlogix-osake noteerataan hintaan 0,08 EUR (0,09 USD).
Resverlogix-osake (RVX.TO) on listattuna 6 pörssissä, muun muassa: London (0VF9.L), Toronto (RVX.TO), Frankfurt (RFS.F), München (RFS.MU), Düsseldorf (RFS.DU).
Resverlogix Corp is a biopharmaceutical company focused on developing drugs that target lipid and lipoprotein metabolism. The company was founded in 2001 and is headquartered in Calgary, Canada. Resverlogix Corp specializes in the discovery and development of therapeutics for the treatment of serious diseases such as Alzheimer's, Parkinson's, cancer, and diabetes.
Liikevaihtoa ei voida laskea Resverlogix:lle tällä hetkellä.
Voittoa ei voida laskea Resverlogix:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Resverlogix:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Resverlogix:lle tällä hetkellä.
Resverlogix:n Eulpool-laatuscore on 2/10.
Resverlogix:n ISIN on CA76128M1086. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Resverlogix:n WKN on A0DP7L. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Resverlogix:n ticker on RVX.TO. Tämä pörssinoteeraus käytetään Resverlogix-osakkeiden kauppaan pörssissä.
Resverlogix osake
Resverlogix vertaisryhmä
Resverlogix Ticker
Resverlogix FIGI
Kaikki tunnusluvut ja syvällinen analyysi Resverlogix:sta
Meidän osakeanalyysimme Resverlogix-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Resverlogix:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: